CAJ | 학술논문

笔者通过检索中国专利检索系统文摘数据库（CPRSABS），对1992-2013年间治疗获得性免疫缺陷综合征（AIDS）的核苷类逆转录酶抑制剂恩曲他滨、替诺福韦及两者的复方制剂在中国的专利保护现状进行分析，为中国企业和研究机构提供专利预警和应对建议，使其在药物研发、专利保护方面更加有针对性，更准确地把握临床应用趋势，赢得市场。
필자통과검색중국전리검색계통문적수거고（CPRSABS），대1992-2013년간치료획득성면역결함종합정（AIDS）적핵감류역전록매억제제은곡타빈、체낙복위급량자적복방제제재중국적전리보호현상진행분석，위중국기업화연구궤구제공전리예경화응대건의，사기재약물연발、전리보호방면경가유침대성，경준학지파악림상응용추세，영득시장。
This paper analyzed Chinese patent situations of nucleoside analogue reverse transcriptase inhibitor emtricitabine, tenofovir and their compound preparation for AIDS treatment from 1992-2013, based on CPRSABS database. Some protective strategy of patent early warning and corresponding suggestions were provided for the domestic companies and research institutions in order to protect patent and research drug more effectively, grasp clinical trend accurately and win the market.